Audited Financial Results & Audit Report for the Quarter and Year ended March 31,2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Chemo Pharma Laboratories Limited reported audited results for FY25 showing a sharp deterioration in performance. Revenue from operations fell dramatically to ₹6,198 thousand in FY25 from ₹18,382 thousand in FY24, a decline of roughly 66%. The company swung to a loss after tax of ₹(2,914) thousand in FY25 compared to a profit of ₹3,422 thousand in FY24. Basic EPS turned negative at ₹(2.26) versus ₹2.28 last year. Operating cash flow also turned negative at ₹(2,824.50) thousand versus ₹7,236.29 thousand in FY24. The auditor (Sanjay Rane & Associates LLP) issued an unmodified/unqualified opinion on the financial statements. However, the auditor included an Emphasis of Matter noting that an inter-corporate deposit of ₹2.20 crore given to a related party (Solding Hydrowatt Private Limited) may not have been priced at arm's length, potentially leading to under-reported interest income.
Shareholders face a worrying year with revenue collapse, a return to loss-making, negative operating cash flow, and an auditor red flag on a related-party loan that may be understated. Despite the clean (unmodified) overall opinion, the combination of weak fundamentals and governance concerns around related-party transactions could weigh on investor sentiment.